These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 15494604

  • 1. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR, Hong WK.
    J Natl Cancer Inst; 2004 Oct 20; 96(20):1536-48. PubMed ID: 15494604
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
    Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1272-86. PubMed ID: 16145048
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
    Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM.
    Cancer Res; 2002 Jun 15; 62(12):3530-7. PubMed ID: 12068000
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY.
    Clin Cancer Res; 2008 Mar 01; 14(5):1581-9. PubMed ID: 18316583
    [Abstract] [Full Text] [Related]

  • 5. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS, Eisen TG.
    Int J Cancer; 2003 Jun 10; 105(2):165-75. PubMed ID: 12673674
    [Abstract] [Full Text] [Related]

  • 6. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK.
    Clin Cancer Res; 2005 Aug 15; 11(16):6065-74. PubMed ID: 16115952
    [Abstract] [Full Text] [Related]

  • 7. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
    Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R.
    Cancer Res; 2003 Aug 15; 63(16):4796-800. PubMed ID: 12941797
    [Abstract] [Full Text] [Related]

  • 8. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL.
    Cancer Chemother Pharmacol; 2000 Aug 15; 46(5):387-93. PubMed ID: 11127943
    [Abstract] [Full Text] [Related]

  • 9. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
    Sun SY, Zhou Z, Wang R, Fu H, Khuri FR.
    Cancer Biol Ther; 2004 Nov 15; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
    [Abstract] [Full Text] [Related]

  • 10. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
    Loprevite M, Favoni RE, De Cupis A, Scolaro T, Semino C, Mazzanti P, Ardizzoni A.
    Oncol Rep; 2004 Feb 15; 11(2):407-14. PubMed ID: 14719076
    [Abstract] [Full Text] [Related]

  • 11. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
    Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH.
    Clin Cancer Res; 2001 May 15; 7(5):1438-45. PubMed ID: 11350915
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
    Glass TL, Liu TJ, Yung WK.
    Neuro Oncol; 2000 Jul 15; 2(3):151-8. PubMed ID: 11302335
    [Abstract] [Full Text] [Related]

  • 13. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
    Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.
    Oncotarget; 2016 Jan 26; 7(4):4265-78. PubMed ID: 26673006
    [Abstract] [Full Text] [Related]

  • 14. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
    Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY.
    Clin Cancer Res; 2006 Jan 15; 12(2):653-61. PubMed ID: 16428512
    [Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
    Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH, Glisson BS, Kim YH, Lee HY.
    Int J Cancer; 2012 Nov 15; 131(10):2253-63. PubMed ID: 22362554
    [Abstract] [Full Text] [Related]

  • 16. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
    Cho Y, Park MJ, Park M, Min SS, Yee J, Kim C, Han MS, Han SH.
    Respirology; 2009 Aug 15; 14(6):850-8. PubMed ID: 19703066
    [Abstract] [Full Text] [Related]

  • 17. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM, Lau N, Roncari L, Guha A.
    Cancer Res; 2001 Jun 01; 61(11):4425-31. PubMed ID: 11389071
    [Abstract] [Full Text] [Related]

  • 18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 20. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.
    Clin Cancer Res; 2005 Feb 15; 11(4):1563-71. PubMed ID: 15746061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.